VDR and cancer: Many studies have shown that mutant forms of TP53 bind to several transcription factors, including SP1, ETS1, ETS2, VDR, SREBP-2, and NF-Y, altering expression of their target genes to produce gain-of-function properties.8,21,23 We showed that TP53R273H interacts with BCAR1 in the nucleus and that the TP53 transactivation domain and the nuclear localisation of both TP53R273H and BCAR1 are required to promote cancer cell invasion.